Do you want to read an article? Please log in or register.
Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study
Gynecologic Cancer
Related content
Breast Cancer
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2
J Clin Oncol
Phillips KA, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, Aeilts AM, Andrulis IL, Buys SS, Cui W, Daly MB, Eisen AF, Foulkes WD, Friedlander ML, Gronwald J, Hopper JL, John EM, Karlan BY, Kim RH, Kurian AW, Lubinski J, Metcalfe K, Nathanson KL, Singer CF, Southey MC, Symecko H, Tung N, Narod SA, Milne RL, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the Basser Center University of Pennsylvania Registry, and the Breast Cancer Family Registry, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the Basser Center University of Pennsylvania Registry and the Breast Cancer Family Registry
doi: 10.1200/JCO.24.00176
Genitourinary Cancer
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
Eur Urol
Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP
doi: 10.1016/j.eururo.2025.04.017
Gynecologic Cancer
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
Lancet Oncol
Sundar S, Agarwal R, Davenport C, Scandrett K, Johnson S, Sengupta P, Selvi-Vikram R, Kwong FL, Mallett S, Rick C, Kehoe S, Timmerman D, Bourne T, Van Calster B, Stobart H, Neal RD, Menon U, Gentry-Maharaj A, Sturdy L, Ottridge R, Deeks J, ROCkeTS collaborators
doi: 10.1016/S1470-2045(24)00406-6
Gynecologic Cancer
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study
Int J Cancer
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, Odicino F, Perrone F, Chiodini P, Pignata S
doi: 10.1002/ijc.35203
Breast Cancer
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study
Lancet Oncol
Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA Jr, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M
doi: 10.1016/S1470-2045(25)00152-4
Genitourinary Cancer
Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study
Adv Ther
Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, Chilelli A, Stoelzel M, Serikoff A, Spitzer SG
doi: 10.1007/s12325-025-03132-8
Breast Cancer
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
Eur J Cancer
Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E
doi: 10.1016/j.ejca.2024.115219
COMMENTED
Gynecologic Cancer
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR, ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators
doi: 10.1016/S0140-6736(24)01808-7
SPECIAL REPORT
Breast Cancer